Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: muscarinic receptor agonists - Mithridion

Drug Profile

Research programme: muscarinic receptor agonists - Mithridion

Alternative Names: CDD-0097; CDD-0098J; CDD-0199J; CDD-0304; CDD-0312; CDD-0313; CDD-0314; CDD-0316; CDD-0317; CDD-0322; MI-10-022

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Toledo
  • Developer Mithridion
  • Class Piperidines; Small molecules; Thiadiazoles
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Alzheimer's disease; Schizophrenia

Highest Development Phases

  • No development reported Alzheimer's disease; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA
  • 12 Jan 2011 Research programme: muscarinic receptor agonists - Mithridion is available for licensing as of 12 Jan 2011. http://www.mithridion.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top